Revance Therapeutics Inc (RVNC)
2.925
-0.08
(-2.82%)
USD |
NASDAQ |
May 22, 16:00
2.925
0.00 (0.00%)
After-Hours: 20:00
Revance Therapeutics Cash from Financing (Quarterly): 92.83M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 92.83M |
| December 31, 2023 | -1.629M |
| September 30, 2023 | 37.46M |
| June 30, 2023 | 97.47M |
| March 31, 2023 | 3.265M |
| December 31, 2022 | -6.173M |
| September 30, 2022 | 211.39M |
| June 30, 2022 | 21.16M |
| March 31, 2022 | 105.31M |
| December 31, 2021 | 0.405M |
| September 30, 2021 | -2.492M |
| June 30, 2021 | 2.912M |
| March 31, 2021 | 29.04M |
| December 31, 2020 | 67.32M |
| September 30, 2020 | -0.687M |
| June 30, 2020 | 0.50M |
| March 31, 2020 | 264.35M |
| December 31, 2019 | 114.83M |
| September 30, 2019 | -0.081M |
| June 30, 2019 | 0.043M |
| March 31, 2019 | 106.87M |
| December 31, 2018 | 0.164M |
| September 30, 2018 | 0.895M |
| Date | Value |
|---|---|
| June 30, 2018 | 2.945M |
| March 31, 2018 | -2.222M |
| December 31, 2017 | 158.67M |
| September 30, 2017 | 9.123M |
| June 30, 2017 | 3.154M |
| March 31, 2017 | 25.00M |
| December 31, 2016 | -0.668M |
| September 30, 2016 | -0.664M |
| June 30, 2016 | -0.707M |
| March 31, 2016 | -0.603M |
| December 31, 2015 | 127.05M |
| September 30, 2015 | 9.351M |
| June 30, 2015 | 8.753M |
| March 31, 2015 | -2.563M |
| December 31, 2014 | -5.801M |
| September 30, 2014 | -1.105M |
| June 30, 2014 | 130.04M |
| March 31, 2014 | 105.96M |
| December 31, 2013 | 19.79M |
| September 30, 2013 | -2.19M |
| June 30, 2013 | 6.733M |
| March 31, 2013 | 29.66M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-6.173M
Minimum
Dec 2022
264.35M
Maximum
Mar 2020
51.86M
Average
12.22M
Median
Cash from Financing (Quarterly) Benchmarks
| AbbVie Inc | 10.82B |
| Eli Lilly and Co | -311.30M |
| Aquestive Therapeutics Inc | 81.74M |
| Humacyte Inc | 62.80M |
| AN2 Therapeutics Inc | 0.349M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -65.94M |
| Cash from Investing (Quarterly) | -31.71M |
| Free Cash Flow | -224.20M |
| Free Cash Flow Per Share (Quarterly) | -0.7736 |
| Free Cash Flow to Equity (Quarterly) | -71.86M |
| Free Cash Flow Yield | -87.81% |